The pivotal role of macrophages in tumorigenesis and pioneering cancer immunotherapy across pre-clinical and clinical frontiers.
6 affiliations
- 1Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- 2Research Center for Prevention of Oral and Dental Diseases, Baqiyatallah University of Medical Sciences, Tehran, Iran.
- 3Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran.
- 4Farhikhtegan Medical Convergence Sciences Research Center, Farhikhtegan Hospital, TeMS. C., Islamic Azad University, Tehran, Iran.
- 5School of Medicine, Iran University of Medical Science, Tehran, Iran.
- 6Nephrology and Urology Research Center, Clinical Sciences Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran. [email protected].
Abstract
Tumor-associated macrophages (TAMs) are among the most abundant cells in the tumor microenvironment (TME), with M1 and M2 polarization exhibiting anti-tumorigenic and tumorigenic functions, respectively. Originating from both embryonic precursors and circulating monocytes derived from hematopoietic stem cells, TAMs acquire distinct transcriptional, metabolic, and functional identities shaped by the TME. The interactions in the TME among various cells, including cancerous and non-cancerous cells, can determine the polarization and function of TAMs within the tumor. More recently, TAMs have garnered significant interest as a promising therapeutic target in oncology. The TAMs have been shown to enhance proliferation, metastasis, and angiogenesis in human cancers. Notably, cytokines and chemokines, among others, can regulate the infiltration of TAMs in TME. Given the crucial role of macrophages in regulating inflammation and immune responses, targeting these cells has become a significant focus in cancer immunotherapy. Currently, macrophages have been targeted through three strategies, including suppressing macrophage/monocyte recruitment, depletion of TAMs, and re-education of TAMs. Each of these approaches is being investigated in preclinical models and clinical trials, either as monotherapy or in combination with immune checkpoint inhibitors. TAMs can also be engineered to act as drug delivery tools, carrying nanoparticles directly into tumors. In the clinic, some types of TAMs, marked by proteins like CD163 and CD204, can help predict patient outcomes in several cancers. This review investigates the origins of TAMs and the mechanisms underlying their polarization and metabolism. Furthermore, we study macrophage-driven tumor progression and devising effective targeting strategies, as well as challenges that remain and where the field may go next in macrophage-based cancer treatment. Going forward, combining single-cell profiling with multi-target therapies may offer the best path toward more effective, TAM-based cancer treatments.
Related
- Precision targeting of tumor-associated macrophages via a 6-substituted pyrrolo[2,3-d]pyrimidine chimeric molecule for enhanced cancer immunotherapy
- Engineered Inflammation-Triggering Macrophages (MacTrigger) Synergize Anti-CD47 Immunotherapy While Sparing Normal Tissues
- Macrophage state in neoadjuvant and perioperative immunotherapy resistance in resectable NSCLC: a critical appraisal of strategies from CSF1R and CD47–SIRPα to CAR-macrophages
- Tumor-associated macrophages in glioblastoma: implications for immunotherapy
- Advancing Electrochemotherapy in Melanoma and Non-Melanoma Skin Cancer: From Clinical Practice to Emerging Frontiers.
BibTeX
@article{alimohammadi2026pivotal,
title = {{The pivotal role of macrophages in tumorigenesis and pioneering cancer immunotherapy across pre-clinical and clinical frontiers.}},
author = {Mina Alimohammadi and Amir Mohammad Mirnejad and Najma Farahani and Neda Hedayati and Kiavash Hushmandi},
journal = {Journal of cancer research and clinical oncology},
year = {2026},
month = jul,
doi = {10.1007/s00432-026-06566-x},
url = {https://europepmc.org/article/MED/42911425},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - The pivotal role of macrophages in tumorigenesis and pioneering cancer immunotherapy across pre-clinical and clinical frontiers.
AU - Mina Alimohammadi
AU - Amir Mohammad Mirnejad
AU - Najma Farahani
AU - Neda Hedayati
AU - Kiavash Hushmandi
PY - 2026
DA - 2026/07/01
JO - Journal of cancer research and clinical oncology
DO - 10.1007/s00432-026-06566-x
UR - https://europepmc.org/article/MED/42911425
AB - Tumor-associated macrophages (TAMs) are among the most abundant cells in the tumor microenvironment (TME), with M1 and M2 polarization exhibiting anti-tumorigenic and tumorigenic functions, respectively. Originating from both embryonic precursors and circulating monocytes derived from hematopoietic stem cells, TAMs acquire distinct transcriptional, metabolic, and functional identities shaped by the TME. The interactions in the TME among various cells, including cancerous and non-cancerous cells, can determine the polarization and function of TAMs within the tumor. More recently, TAMs have garnered significant interest as a promising therapeutic target in oncology. The TAMs have been shown to enhance proliferation, metastasis, and angiogenesis in human cancers. Notably, cytokines and chemokines, among others, can regulate the infiltration of TAMs in TME. Given the crucial role of macrophages in regulating inflammation and immune responses, targeting these cells has become a significant focus in cancer immunotherapy. Currently, macrophages have been targeted through three strategies, including suppressing macrophage/monocyte recruitment, depletion of TAMs, and re-education of TAMs. Each of these approaches is being investigated in preclinical models and clinical trials, either as monotherapy or in combination with immune checkpoint inhibitors. TAMs can also be engineered to act as drug delivery tools, carrying nanoparticles directly into tumors. In the clinic, some types of TAMs, marked by proteins like CD163 and CD204, can help predict patient outcomes in several cancers. This review investigates the origins of TAMs and the mechanisms underlying their polarization and metabolism. Furthermore, we study macrophage-driven tumor progression and devising effective targeting strategies, as well as challenges that remain and where the field may go next in macrophage-based cancer treatment. Going forward, combining single-cell profiling with multi-target therapies may offer the best path toward more effective, TAM-based cancer treatments.
SN - 0171-5216
SN - 1432-1335
ER -